Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Common Equity for 13 consecutive years, with $501.9 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 40.74% year-over-year to $501.9 million; the TTM value through Mar 2026 reached $501.9 million, down 40.74%, while the annual FY2025 figure was $639.1 million, 27.4% down from the prior year.
  • Common Equity hit $501.9 million in Q1 2026 for Viking Therapeutics, down from $639.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $933.9 million in Q1 2024 and bottomed at $134.1 million in Q1 2023.
  • Average Common Equity over 5 years is $530.8 million, with a median of $501.9 million recorded in 2026.
  • Year-over-year, Common Equity soared 596.6% in 2024 and then plummeted 40.74% in 2026.
  • Viking Therapeutics' Common Equity stood at $145.3 million in 2022, then soared by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then fell by 27.4% to $639.1 million in 2025, then fell by 21.46% to $501.9 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $501.9 million, $639.1 million, and $713.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.